Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 2;118(3):366–377. doi: 10.1038/bjc.2017.421

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Cancer Research UK

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

PMC Copyright notice

MTOR-based combination therapies. (A) The indicated human and murine cell lines were treated with INK-128, MK-2206, GDC-0941 or PD-325901, or in combinations thereof as indicated. After 72 h, viability was measured in MTT assays. Viability of vehicle-treated control cells was arbitrarily set to 1. (B) Primary human PDAC 3D cultures B20 and B25 were treated with INK-128, MK-2206, GDC-0941 or PD-325901, or in combinations thereof as indicated. After 5 days, ATP levels were measured using a luminometric viability assay. Metabolic activity of untreated cells was arbitrarily set to 1. (C) Synergy score for the combination of the MTOR inhibitor (INK-128) with the AKT (MK-2206), PI3K (GDC-0941) and MEK (PD-325901) inhibitor in 10 human PDAC cell lines, 4 murine PDAC cell lines and 2 primary human PDAC 3D cultures. (D) Comparison of the synergy scores of (C). *P-value of analysis of variance (ANOVA) test <0.05.